SENATE BILL No. 631

DIGEST OF SB 631 (Updated January 16, 2019 12:39 pm - DI 133)

Citations Affected: IC 35-31.5; IC 35-48.

Synopsis: Drug classifications and drug schedules. Adds numerous substances to the definition of "synthetic drug". Adds epidiolex to Schedule V. Specifies that dronabinol is a Schedule II controlled substance only in oral solution.

Effective: July 1, 2019.

Young M

January 15, 2019, read first time and referred to Committee on Rules and Legislative Procedure.
January 16, 2019, amended; reassigned to Committee on Corrections and Criminal Law.
SENATE BILL No. 631

A BILL FOR AN ACT to amend the Indiana Code concerning criminal law and procedure.

Be it enacted by the General Assembly of the State of Indiana:

SECTION 1. IC 35-31.5-2-321, AS AMENDED BY P.L.89-2018, SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2019]: Sec. 321. "Synthetic drug" means:

1 a substance containing one (1) or more of the following chemical compounds, including an analog of the compound:
2 (A) JWH-015 (1-2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone).
3 (B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).
4 (C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).
5 (D) JWH-073 (naphthalen-1-yl-(1-butyldiol-3-yl)methanone).
6 (E) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentyldiol-3-yl)methanone).
7 (F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
8 (G) JWH-200 (1-(1-2-morpholin-4-ylethyl)indol-3-yl)naphthalen-1-yl-methanone).
9 (H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).
(I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
(J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
(K) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
(L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
(M) HU-308 (((1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-
7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
(N) HU-331 (3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-
pentyl-2,5-cyclohexadiene-1,4-dione).
(O) CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-
5- (2-methyloctan-2-yl)phenol).
(P) CP 47,497 (2-[(1R,3S)-3-hydroxy(cyclohexyl)-
5-(2-methyloctan-2-yl)phenol) and its homologues, or
2-[(1R,3S)-3-hydroxy(cyclohexyl)-5-(2-methyloctan-2-yl) phenol), where side chain n=5, and homologues where side
chain n=4, 6, or 7.
(Q) WIN 55212-2 ((R)-(+-)[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone).
(R) RCS-4 ((4-methoxyphenyl)
(1-pentyl-1H-indol-3-yl)methanone).
(S) RCS-8 (1-((1-(2-cyclohexylethyl)-1H-
indol-3-yl)-2-(2-methoxyphenyl)ethanone).
(T) 4-Methylmethcathinone. Other name: mephedrone.
(U) 3,4-Methylenedioxy(methylthecathinone. Other name:
methyline.
(V) Fluoromethcathinone.
(W) 4-Methoxymethcathinone. Other name: methedrone.
(X) 4-Ethylmethcathinone (4-EMC).
(Y) Methylenedioxypyrvalerone. Other name: MDPV.
(Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.
(AA) JWH-098, or
1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.
(BB) JWH-164, or
1-pentyl-3-(7-methoxy-1-naphthoyl)indole.
<table>
<thead>
<tr>
<th>No.</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.</td>
</tr>
<tr>
<td>2</td>
<td>(DD) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole.</td>
</tr>
<tr>
<td>3</td>
<td>(EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.</td>
</tr>
<tr>
<td>4</td>
<td>(FF) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.</td>
</tr>
<tr>
<td>5</td>
<td>(GG) CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-((2R)-5-phenylpentan-2-yl)oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate.</td>
</tr>
<tr>
<td>6</td>
<td>(HH) Dimethylheptylpyran, or DMHP.</td>
</tr>
<tr>
<td>7</td>
<td>(II) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP.</td>
</tr>
<tr>
<td>8</td>
<td>(JJ) 6-APB [6-(2-aminoethyl)benzoic acid].</td>
</tr>
<tr>
<td>9</td>
<td>(LL) 7-hydroxymitragynine.</td>
</tr>
<tr>
<td>10</td>
<td>(MM) α-PPP [α-pyrrolidinopropiophenone].</td>
</tr>
<tr>
<td>11</td>
<td>(NN) α-PVP (desmethylpyrovalerone).</td>
</tr>
<tr>
<td>12</td>
<td>(OO) AM-251.</td>
</tr>
<tr>
<td>13</td>
<td>(PP) AM-1241.</td>
</tr>
<tr>
<td>14</td>
<td>(QQ) AM-2201.</td>
</tr>
<tr>
<td>15</td>
<td>(RR) AM-2233.</td>
</tr>
<tr>
<td>16</td>
<td>(SS) Buphedrone (α-methylamino-butyrophenone (MABP)).</td>
</tr>
<tr>
<td>17</td>
<td>(TT) Butylone.</td>
</tr>
<tr>
<td>18</td>
<td>(UU) CP-47,497-C7.</td>
</tr>
<tr>
<td>19</td>
<td>(VV) CP-47,497-C8.</td>
</tr>
<tr>
<td>20</td>
<td>(WW) Desoxypipradol.</td>
</tr>
<tr>
<td>21</td>
<td>(XX) Ethylone.</td>
</tr>
<tr>
<td>22</td>
<td>(YY) Eutylone.</td>
</tr>
<tr>
<td>23</td>
<td>(ZZ) Flephedrone.</td>
</tr>
<tr>
<td>24</td>
<td>(AAA) JWH-011.</td>
</tr>
<tr>
<td>25</td>
<td>(BBB) JWH-020.</td>
</tr>
<tr>
<td>26</td>
<td>(CCC) JWH-022.</td>
</tr>
<tr>
<td>27</td>
<td>(DDD) JWH-030.</td>
</tr>
<tr>
<td>28</td>
<td>(EEE) JWH-182.</td>
</tr>
<tr>
<td>29</td>
<td>(FFF) JWH-302.</td>
</tr>
<tr>
<td>30</td>
<td>(GGG) MDAI [5,6-methylenedioxy-2-aminoindane].</td>
</tr>
<tr>
<td>31</td>
<td>(HHH) Mitragynine.</td>
</tr>
<tr>
<td>32</td>
<td>(III) Naphyrone.</td>
</tr>
<tr>
<td>33</td>
<td>(JJJ) Pentedrone.</td>
</tr>
<tr>
<td>34</td>
<td>(LLL) Pentylone.</td>
</tr>
<tr>
<td>35</td>
<td>(MMM) Methoxetamine [2-(3-methoxyphenyl)-2-(ethylamino)-cyclohexanone].</td>
</tr>
<tr>
<td>36</td>
<td>(NNN) A796,260</td>
</tr>
</tbody>
</table>
1. [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-
2. (2,2,3,3-tetramethylcyclopropyl)methanone].
3. (OOO) AB-001[(1s,3s)-admantan-1-yl]
4. (1-pentyl-1H-indol-3-yl)methanone] or [1-Pentyl-3-
5. (1-adamantoyl)indole].
6. (PPP) AM-356 [Methanandomide],
7. (QQQ) AM 1248 [1-[(1-methyl-2- piperidinyl) methyl]
8. 1H-indol-3-yl] tricyclo[3.3.1.13,7] dec-1-yl-methanone]or
9. [(1-[(N-methylpiperindin-2-yl)
10. Methyl]-3-(Adamant-1-oyl)indole].
11. (RRR) AM 2233 Azepane isomer [(2-iodophenyl)
12. (1-1-methylazepan-3-yl)- 1H-indol-3-yl)methanone].
13. (SSS) CB-13 [1-Naphthalenyl
15. (TTT) UR-144 [(1-pentyl-1H-indol-3-yl)
16. (2,2,3,3-tetramethylcyclopropyl)-methanone].
17. (UUU) URB 597 [(3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-
18. cyclohexylcarbamate].
19. (VVV) URB602 [(1,1'-biphenyl]- 3-yl-carbamic acid,
20. cyclohexyl ester].
21. (WWW) URB 754 [6-methyl-2-[(4-methylphenyl)
22. amino]-1-benzoazin-4-one].
23. (XXX) XLR-11 or 5-fluoro UR-144
24. (1-(5-fluoropentyl)-1H-indol-3-yl)
25. (2,2,3,3-tetramethylcyclopropyl)methanone].
26. (YYY) AKB48 (Other names include:
27. N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide;
28. 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-
29. carboxamide).
30. (ZZZ) 25I-NBOMe (Other names include:
31. 4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-
32. benzeethanamine);
33. 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
34. methyl]ethanamine).
35. (AAAA) 2C-C-NBOMe (Other names include:
36. 25C-NBOMe;
37. 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
38. methyl]ethanamine;
39. 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)
40. phenethylamine).
41. (BBBB) 2NE-1 (Other names include: 1-Pentyl-3-
42. (1-adamantylamido)indole).
(CCCC) STS-135 (Other names include: N-Adamantyl-1-fluoropentylindole-3-carboxamide (1-5-fluoropentyl)-N-tricyclo[3.3.1.13.7]dec-1-yl-1H-indole-3-carboxamide).

(DDDD) PB-22 (Other names include: 1-Pentyl-8-quinolinyl ester-1H-indole-2-carboxylic acid).

(EEEE) 5-Fluoro-PB-22 (Other names include: 1-(5-Fluoropentyl)-8-quinolinyl ester1H-indole-3-carboxylic acid).

(FFFF) Benocyclidine (Other names include: BCP, BTCP, and Benzo[thiophenylcyclohexylpiperidine).

(GGGG) 25B-NBOMe (Other names include: 2C-B-NBOMe and 4-Bromo-2,5-dimethoxy-N-[2-Methoxyphenyl)methyl]benzeneethanamine).

(HHHH) APB (Other names include: (2-Aminopropyl)Benzofuran).

(IIII) AB-PINACA

(JJJJ) AB-FUBINACA

(KKKK) ADB-PINACA

(LLLL) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobut-2-yl)-(fluoropentyl)-1H-indole-3-carboxamide).

(MMMM) APDB (Other names include: -EMA, -Desoxy-MDA, and (2-Aminopropyl)-2,3-dihydrobenzofuran).

(NNNN) THJ-2201 (Other names include: AM2201 indazole analog, Fluoropentyl-JWH-018 indazole, and 5-Fluoro-THJ-018).

(OOOO) AM 2201 benzimidazole analog (Other names include: FUBIMINA, FTHJ, and (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalene-1-yl)methanone).

(PPPP) MN-25 (Other names include: 7-methoxy-1-[2-(4-morpholinyl)ethyl]-N-[1S, 2S, 4R]-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-indole-3-carboxamide and UR-12).
(QQQQ) FUB-PB-22 (Other names include: Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate).

(RRRR) FUD-PB-22 (Other names include: Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate).

(SSSS) 5-Fluoro-AB-PINACA (Other names include: AB-PINACA 5-fluoro analog and N-(1-amino-3-methyl-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide).

(TTTT) 4-MePPP (Other names include: 4-methyl-alpha-pyrrolidinopropiophenone).

(UUUU) alpha-PBP (Other names include: Alpha-pyrrolidinobutylphenone).

(VVVV) AB-CHMINACA (Other names include: N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide).

(YYYY) MT-45, (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine).

(ZZZZ) N-(1-phenethylpiperidin-4-yl)-N-phenylpentamide (valeryl fentanyl).

(AAAAA) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl fentanyl).

(BBBBB) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-methoxybutyryl fentanyl).

(CCCCC) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide (para-chloroisobutyryl fentanyl).

(DDDDD) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl).

(EEEEEE) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentancarboxamide (cyclopropyl fentanyl).

(FFFFF) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl) acetamide (ocfentanil).

(GGGGG) 4-fluoroisobutyryl fentanyl.

(HHHHH) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA].

(IHHH) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate [5F-AMB].
(JJJJJ) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide [ADB-FUBINACA].

(KKKKK) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide [5F-APINACA, 5F-AKB48].

(LLLLL) methyl 2-(1-cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate [MDMB-CHMINACA, MMB-CHMINACA].

(MMMMM) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [MDMB-FUBINACA].

(NNNNN) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide [MAB-CHMINACA and ADB-CHMINACA].

(OOOOO) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate [FUB-AMB, MMB-FUBINACA, AMB-FUBINACA].

(PPPPP) 3,4-dichloro-N-[1(dimethylamino)cyclohexylmethyl]benzamide) [AH7921].

(QQQQQ) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide, butyryl fentanyl.

(RRRRR) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide, also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4- piperidinyl]-N-phenylpropanamide, (beta-hydroxythiofentanyl).

(SSSSS) Furanyl fentanyl.

(TTTTT) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (trivial name: NM2201; CBL2201)

(UUUUU) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (trivial name: 4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINACA; CUMYL-4CN-BINACA; SGT-78).

(VVVVV) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (trivial names: MMB-CHMIC, AMB-CHMIC).

(WWWWWW) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (trivial name: 5F-CUMYL-P7AICA).
(XXXXX) N-1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone (N-ethylpentylone, ephylone).

(YYYYY) Synthetic cathinone,

1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone) and its optical, positional, and geometric isomers, salts, and salts of isomers.

(2) Any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(3) Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(4) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(5) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

(6) Any compound structurally derived from
2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position
of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not substituted in the cyclohexyl ring to any extent.

(7) Any compound containing a 3-(benzoyl)indole structure with
substitution at the nitrogen atom of the indole ring by alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indole ring to any extent and
whether or not substituted in the phenyl ring to any extent.

(8) Any compound, except bupropion or a compound listed under
a different schedule, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with either
phenyl, naphthyl, or thiophene ring systems, whether or not the
compound is further modified:

(A) by substitution in the ring system to any extent with alkyl,
alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
substituents, whether or not further substituted in the ring
system by one or more other univalent substituents;
(B) by substitution at the 3-position with an acyclic alkyl
substituent;
(C) by substitution at the 2-amino nitrogen atom with alkyl,
dialkyl, benzyl, or methoxybenzyl groups; or
(D) by inclusion of the 2-amino nitrogen atom in a cyclic
structure.

(9) Any compound structurally derived from 3-tetramethyl
cyclopropanoylindole with substitution at the nitrogen atom of the
indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indole ring to any extent and
whether or not substituted in the tetramethylcyclopropyl ring to
any extent.

(10) Any compound containing a N-(1-adamantyl)-
1H-indazole-3-carboxamide structure with substitution at the
nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted at the nitrogen atom of the carboxamide to any extent, whether or not further substituted in the indazole ring to any extent, and whether or not further substituted on the adamantyl ring system to any extent. An example of this structural class includes AKB48.

(11) Any compound containing a N-(1-adamantyl)-1H-indole-3-carboxamide structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted at the nitrogen atom of the carboxamide to any extent, whether or not further substituted in the indole ring to any extent, and whether or not further substituted on the adamantyl ring system to any extent. An example of this structural class includes STS-135.

(12) Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted on the adamantyl ring system to any extent. An example of this structural class includes AM-1248.

(13) Any compound determined to be a synthetic drug by rule adopted under IC 25-26-13-4.1.

SECTION 2. IC 35-48-2-6, AS AMENDED BY P.L.89-2018, SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2019]: Sec. 6. (a) The controlled substances listed in this section are included in schedule II.

(b) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrophan, nalbuphine, naloxone, naltrexone, and their respective salts but including:

(A) raw opium (9600);
(B) opium extracts (9610);
(C) opium fluid extracts (9620);
(D) powdered opium (9639);
(E) granulated opium (9640);
(F) tincture of opium (9630);
(G) codeine (9050);
(H) dihydroetorphine (9334);
(I) ethylmorphine (9190);
(J) etorphine hydrochloride (9059);
(K) hydrocodone (9193), and any hydrocodone combination product, as determined by the federal Food and Drug Administration;
(L) hydromorphone (9150);
(M) metopon (9260);
(N) morphine (9300);
(O) oxycodone (9143);
(P) oxymorphone (9652);
(Q) thebaine (9333); and
(R) oripavine.

(2) Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subdivision (b)(1) of this section, but not including the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Cocaine (9041).

(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy) (9670).

(c) Opiates. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

Alfentanil (9737)
Alphaprodine (9010)
Anileridine (9020)
Bezitramide (9800)
Bulk dextropropoxyphene (nondosage forms) (9273)
Carfentanil (9743)
Dihydrocodeine (9120)
Diphenoxylate (9170)
Fentanyl (9801)
Isomethadone (9226)
Levo-alpha-acetylmethadol (9648). Other names:
Levo-alpha-acetylmethadol; levomethadyl acetate; and LAAM.
Levomethorphan (9210)
Levorphanol (9220)
Metazocine (9240)
Methadone (9250)
Methadone-Intermediate, 4-cyano-2-dimethyl-amino-4,
4-diphenyl butane (9254)
Moramide-Intermediate, 2-methyl-3-morpholino-1,
1-diphenylpropane-carboxylic acid (9802)
Pethidine (Meperidine) (9230)
Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine
(9232)
Pethidine-Intermediate-B,
ethyl-4-phenylpiperidine-4-carboxylate (9233)
Pethidine-Intermediate-C,1-methyl-4-phenylpiperidine-4-carbo
xylate (9234)
Phenazodine (9715)
Piminoedine (9730)
Racemethorphan (9732)
Racemorphan (9733)
Remifentanil (9739)
Sufentanil (9740)
Tapentadol
(d) Stimulants. Any material compound, mixture, or preparation
which contains any quantity of the following substances having a
potential for abuse associated with a stimulant effect on the central
nervous system:
(1) Amphetamine, its salts, optical isomers, and salts of its optical
isomers (1100).
(2) Methamphetamine, including its salts, isomers, and salts of its
isomers (1105).
(3) Phenmetrazine and its salts (1631).
(4) Methylphenidate (1724).
(5) Lisdexamfetamine, its salts, its isomers, and salts of its
isomers.
(e) Depressants. Unless specifically excepted by rule of the board
or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- Amobarbital (2125)
- Glutethimide (2550)
- Pentobarbital (2270)
- Phencyclidine (7471)
- Secobarbital (2315)

(f) Immediate precursors. Unless specifically excepted by rule of the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

1. Immediate precursor to amphetamine and methamphetamine:
   - Phenylacetone (8501). Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone.

2. Immediate precursors to phencyclidine (PCP):
   - (A) 1-phenylcyclohexylamine (7460); or
   - (B) 1-piperidinocyclohexanecarbonitrile (PCC) (8603).

3. Immediate precursor to fentanyl:
   - 4-Anilino-N-Phenethyl-4-Piperidine (ANPP).

(g) Hallucinogenic substances:

- Dronabinol oral solution. Other name: (-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC).
- Nabilone (7379). Other name: (+/-)-trans-3-(1,1-dimethylheptyl)-6a, 7, 8, 10, 10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo [b,d] pyran-9-one.

SECTION 3. IC 35-48-2-12, AS AMENDED BY P.L.283-2013, SECTION 4, IS AMENDED TO READ AS FOLLOWS [ EFFECTIVE JULY 1, 2019]: Sec. 12. (a) The controlled substances listed in this section are included in schedule V.

(b) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in the following quantities, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the narcotic drug alone:

SB 631—LS 7594/DI 13
(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
(6) Not more than 0.5 milligrams of difenoxin (9168), and not less than 25 micrograms of atropine sulfate per dosage unit.
(c) Pregabalin (2782).
(d) Pyrovalerone (1485).
(e) Lacosamide [(R)-2-acetamido-N-benzyl-3-methoxy-propionamide].
(f) Epidiolex.
COMMITTEE REPORT

Madam President: The Senate Committee on Rules and Legislative Procedure, to which was referred Senate Bill No. 631, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Delete everything after the enacting clause and insert the following:

(SEE TEXT OF BILL)

and when so amended that said bill be reassigned to the Senate Committee on Corrections and Criminal Law.

(Reference is to SB 631 as introduced.)

BRAY, Chairperson